PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

INTRODUCTION: The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance significantly reduced the risk of disease progression (hazard ratio = 0.62) and death (hazard ratio = 0.78) versus placebo in patients with advanced nonsquamous non–small-cell lung cancer. To further un...

Descripción completa

Detalles Bibliográficos
Autores principales: Reck, Martin, Paz-Ares, Luis G., de Marinis, Filippo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, John, William, Zimmermann, Annamaria H., Visseren-Grul, Carla, Gridelli, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132027/
https://www.ncbi.nlm.nih.gov/pubmed/24419418
http://dx.doi.org/10.1097/JTO.0000000000000076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132027/
https://www.ncbi.nlm.nih.gov/pubmed/24419418
http://dx.doi.org/10.1097/JTO.0000000000000076

Ejemplares similares